FDA OKs Levemir for diabetes

Shares of Denmark's Novo Nordisk have been on the rise since the FDA announced that it had approved Levemir for diabetes. Levemir will be introduced into the US market sometime over the next 12 months. "The US approval of Levemir is an important event for Novo Nordisk in the US as it completes our portfolio of insulin analogues and thereby paves the way for continued expansion of our US diabetes care franchise," said Kaare Schultz, executive vice president and COO at Novo Nordisk.

- read this article from AFX for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.